Actively Recruiting

Phase 1
Phase 2
Age: 20Years - 80Years
All Genders
NCT03579836

Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer

Led by BeyondBio Inc. · Updated on 2025-03-10

75

Participants Needed

1

Research Sites

450 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is a single center, open-label, non-comparative, phase I/II clinical trial to assess the maximum tolerated dose (MTD), safety and efficacy of BEY1107 in monotherapy and in combination with gemcitabine in patient With locally advanced or metastatic pancreatic cancer.

CONDITIONS

Official Title

Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer

Who Can Participate

Age: 20Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histological or cytological confirmation of pancreatic ductal adenocarcinoma or undifferentiated carcinoma of the pancreas
  • At least one measurable tumor lesion according to RECIST version 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  • Life expectancy longer than 12 weeks
  • Adequate bone marrow, kidney, and liver function at screening
Not Eligible

You will not qualify if you...

  • Previous treatment for locally advanced or metastatic pancreatic cancer
  • History of major surgery at screening
  • Evidence of uncontrolled brain metastasis
  • Presence of active bacterial infection
  • Other malignant tumors except basal cell carcinoma, cervical carcinoma in situ, or papillary thyroid cancer
  • Pregnant or breastfeeding women
  • Infection with HIV, active hepatitis B or C
  • Known allergy to BEY1107 or gemcitabine

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Yonsei University Health System Severance Hospital

Seoul, South Korea

Actively Recruiting

Loading map...

Research Team

B

BeyondBio Inc.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here